Diligence memo · auto-generated · as of July 2, 2026
Juno Therapeutics, Inc.
Juno Therapeutics, Inc. has raised $1.1B over 5 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Juno Therapeutics, Inc. operates in Biotechnology, based in SEATTLE. Homepage - Juno Pharmaceuticals
Sub-sector tags: ai/ml, pharma.
Capital & rounds (filed)filed
Juno Therapeutics, Inc. has raised $1.1B in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $898M on 2015-06-29.
Most recent recorded round closed around 2017-09-26.
Valuation (modeled)modeled
Provath models Juno Therapeutics, Inc. at approximately $1.3B (range $194M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 8.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 28.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Theranos Inc, Moderna Therapeutics, Inc., Allogene Therapeutics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.